Compare OCC & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OCC | CVM |
|---|---|---|
| Founded | 1983 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.1M | 53.1M |
| IPO Year | 1996 | 1987 |
| Metric | OCC | CVM |
|---|---|---|
| Price | $8.05 | $6.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 41.0K | ★ 60.3K |
| Earning Date | 12-22-2025 | 01-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $72,694,849.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.67 | N/A |
| 52 Week Low | $2.03 | $1.98 |
| 52 Week High | $11.50 | $32.70 |
| Indicator | OCC | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 52.92 | 42.86 |
| Support Level | $7.81 | $5.56 |
| Resistance Level | $8.69 | $7.80 |
| Average True Range (ATR) | 0.62 | 0.57 |
| MACD | 0.14 | 0.05 |
| Stochastic Oscillator | 76.16 | 39.73 |
Optical Cable Corp manufactures tight-buffered fiber optic & copper data communication cables, data communication connectivity solutions for enterprise markets, and customized solutions for specialty use & harsh environments. Its products and services include designs and customized products for specialty applications and harsh environments, cabling, connectors, patch cords, assemblies, racks, cabinets, datacom enclosures, patch panels, faceplates, and multi-media boxes. The company supplies its products and services to industries such as the military, industrial, mining, petrochemical, renewable energy and broadcast applications, and for the wireless carrier market.
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.